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S Basavaraj, G.V. Betageri41. Introduction
The discovery of new drug is a multi-stage complex process, each stage
lasting for years. Probability of molecule discovered in early stages
making it to market is 1 in 10,0001. In addition to complexities in the
science of making new safe and efﬁcacious drugs, the political,
economic factors coupled with stringent regulatory requirements and
review process, the drug discovery has become even more complex and
long lasting2. As a result, the cost of inventing a new drug has increased
to staggering USD 2.6 billion from 100 million during 19793–5.
Pharmaceutical industry is being criticized for not bringing
more innovative medicine into market for treatment of unmet
medical needs. These days, industry is producing too many drugs
which are similar to each other and offer marginal advantage over
existing treatment. These “me too” drugs although provide
alternative treatment options but led to price competition and
reduced proﬁt margins before the entry of generic versions in the
market6. Since regulatory approval process for “me too” drugs is
relatively fast and easy as these are structurally similar to approved
drugs and hence the pharmaceutical companies tend to focus on
analog research rather than real innovative medicine. Hence there
has been innovation deﬁcit in pharmaceutical R&D these days7.
The sharp decline in the number of new drug approvals in the
last decade can be attributed to attrition of molecules during
discovery and development. The attrition rate is very high in the
drug development process, only 15% of molecules entering the
clinical trials receive marketing approval8. The success rate from
phase-III clinical trial to market translation is reported to be 50–
70%. The molecules are dropped during preclinical stage and
withdrawn from further development during clinical studies for
various reasons, such as lack of efﬁcacy, toxicity, poor absorption,
distribution, metabolism and elimination (ADME) properties,
commercial interest and market competition9,10. The survey of
molecule in clinical development from 1964–1985 revealed thatFigure 1 Representative scheme for drug discovery andpoor pharmacokinetic proﬁle contributed majorly (39.4%) for
attrition of molecules in clinical development9, however ﬁgure
dropped to 10% in 2000, thanks to advancement in formulation
technologies10. Lack of efﬁcacy (30%) and unacceptable clinical
safety and toxicity (30%) were found to be major factors for
discontinuation of clinical candidates in 200010.
There have been several approaches discussed in the literature
to reduce attrition of drug candidates in the clinical development10,
identiﬁcation of right target and strong mechanism of action would
reduce the failure with regard efﬁcacy, the attrition due to toxicity
and safety can be reduced by eliminating molecules with mechan-
ism based toxicity, the identiﬁcation of biomarkers, selection of
appropriate animal model for efﬁcacy testing, evaluating proof of
concept at early clinical studies were suggested for reducing
attrition10.
The failure of drug candidates may not be limited to fore
mentioned reasons, there are other several factors contributing to
attrition, for example discovery and development of drug candi-
dates for central nervous system (CNS) disorders face additional
barriers than those intended for other therapeutic application11.
The CNS drugs while exerting activity, may also led to unwanted
changes in the brain physiology and neurochemical balance, hence
the stringent safety requirements for these drugs. In addition, the
blood brain barrier (BBB) also poses another barrier for develop-
ment of drug candidates in CNS category. The several drug
candidates reported to be dropped due to their inability to cross
BBB. The Gavestinel which had completed phase III clinical trials
but was failed to demonstrate clear efﬁcacy due to its poor
permeation across BBB11. Although there have been signiﬁcant
innovative solutions to address the ADME issues such as absorp-
tion by enhancing solubility and permeability of molecules.
However issues such as rapid metabolism, especially ﬁrst pass
effects have met with limited success. Good example is resveratrol
(RSV), a natural biochemical with diverse biological activity hasdevelopment with reasons for attrition at each stage.
Figure 2 BCS classiﬁcation system and possible ways make most of
molecules into Class I.
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body (half-life of 0.13 h) and only absorbed as metabolites after
oral administration due to complete presystemic metabolism12.
The biological drug candidates such as therapeutic peptides,
proteins and antibodies intended for various therapeutic applica-
tions are prone for destabilization by proteolytic enzymes in the
body and also precipitate unwanted immunogenic reactions and
hence speciﬁc delivery technologies are necessary to enhance
chances of their drugability13. The excess of drug in the circulation
and body tissues other than site of action may lead to toxicity.
Narrow biological difference in the host and cancer cells makes
chemotherapy more challenging, often antineoplastic agents are
toxic chemicals and biologics designed to kill the cancer cells,
while exerting desired pharmacological effects, they precipitate
severe toxic effects14. Hence there is need for technologies to
address various issues in preclinical and clinical development of
drug candidates which lead to attrition. The formulation and drug
delivery technologies have been tested for their utility to enable
candidates at preclinical and clinical developmental stages to
further stages. There are few reports suggesting how formulation
strategies are explored in drug discovery and development;
however, most of them tend to focus on solubility and perme-
ability issues15–18. Hence this review aims to provide comprehen-
sive information on how formulation and drug delivery
technologies can be explored to overcome various challenges in
drug discovery and development. The review discusses the
examples of drug delivery technologies applied for enhancing
therapeutic utility and safety proﬁle of already marketed drugs,
provides insight to how drug delivery can be better explored in the
early stage of discovery and development to reduce the attrition.
In addition, this review also brieﬂy summarizes drug delivery
research; especially proliposomes based oral delivery in our lab
that can be explored for enabling drug candidates to reach market.2. Formulation/drug delivery strategies for addressing
ADMEs issues
The discovery and development of drug involves various stages.
The ﬂow chart in Fig. 1 depicts simpliﬁed drug discovery
and development process19. The hunt for new drug starts with
selecting disease and identiﬁcation of target. The molecules
from synthesis or biological origin would normally be screened
for in vitro biological activity. The selected molecules then move
to further preclinical testing such as in vivo activity in animal
models, in vitro metabolism and pharmacokinetic proﬁling in
animals. During this stage molecules will also be tested forphysicochemical properties such solubility, ionization and partition
behavior. The molecules with desired activity, ADME and
physicochemical properties will undergo stringent safety and
toxicity testing before they enter clinical testing. The physico-
chemical parameters coupled with ADME testing will assist in
determining drugability of molecules. The biopharmaceutics
classiﬁcation system (BCS) groups molecules into four classes
based on solubility and permeability as shown in Fig. 220. The
molecules belonging to Class I are believed to more development
friendly as they possess desired characteristics which make them
more drugable. The molecules belonging to Classes II–IV will
have problems associated with either solubility and/or permeabil-
ity. Lipinski0s rule of ﬁve also provides useful information on
biopharmaceutical behavior of molecules based on molecular
weight H bond donors/acceptors and log P values21. The mole-
cules which lack desired ADME proﬁle will fail to elicit
pharmacological activity in vivo. The importance of early ADME
prediction and proﬁling has been reported in the literature and
early ADME proﬁling found to improve output of discovery22.
The many hits during discovery fail to become lead candidate for
clinical development due to poor ADME properties. The formula-
tion approaches that can improve ADME proﬁle of molecule
amenable for further development are discussed here.2.1. Formulation approaches for improving solubility
Poor solubility leads to incomplete absorption and solubility of
molecules becomes problem in early stages of discovery23.
An estimated 70% of molecules in the developmental pipeline
are believed to be poorly soluble and 40% of already approved
drugs are poorly soluble24. There have been several inventions in
the formulation science that led to viable technologies for the
formulation of poorly soluble drugs to improve delivery.
The buffering/salt formation, cyclodextrin complexation, nanosuspen-
sions, emulsion/microemulsion systems, cosolvency and surfactant
solubilization are commonly used technologies for delivery of
insoluble drugs.
Salt formation has been considered simple and most effective
method for improving solubility and dissolution rate of weakly
acidic and basic drugs25. The salt formation provides viable
strategies for molecules with solubility as rate limiting in their
development. There are several drugs on market as salt forms such
as nelfanavir mesylate, atazenavir sulfate, ziprasidone hydrochlor-
ide and mesylate, imatinib mesylate, indanvir sulfate, metformin
hydrochloride, amlodipine besylate, losartan potassium, diclofenac
sodium and potassium, sodium valproate, and ketrolac trometha-
mine. For many of these molecules, selection of appropriate salt
forms had enhanced their developability into clinical candidates
and ﬁnally to marketing approval. Apart from salt approach, the
buffering/pH adjustment is widely used in the preclinical formula-
tion development of insoluble molecules26. Nearly 85% of
molecules from one of the Pﬁzer research facilities were for-
mulated with pH adjustment and cosolvency in the year 200026.
Similarly many of parenteral formulations on the market contain
counter ions for pH modiﬁcations, examples include Ciproﬂoxacin
Injection, Leurolide, Vincristine, Trimethoprim/Sulfamethaxazole
and Methylprednisolone Injections27.
Cyclodextrins have been explored extensively for formulation
of insoluble molecules. The cyclodextrins are versatile excipients
used in oral and parenteral formulations and choice of excipient for
solubilization of new chemical entities (NCEs) in the preclinical
S Basavaraj, G.V. Betageri6development28,29. The DRF-4367 a weakly acidic NCE had an oral
bioavailability of 20% after oral administration as suspension to
rats; however, solubilized formulation with hydroxy propyl-β-
cyclodextrin and meglumine enhanced bioavailability of molecule
nearly to 100%, thus enabling molecule for further development29.
The administration of molecules in the form of nanosuspension
has shown to increase the oral bioavailability. The formulation of
molecules as nanosupension in the early preclinical development
offers simple, safe and cost effective formulation strategies for
formulation of insoluble NCEs. There are many simple lab based
instrumentation and techniques described in the literature to
produce nanosuspension for the preclinical applications30. The
nanosuspension of DRF-4367 with mean particle size of 100–
300 nm prepared using bead milling followed by high pressure
homogenization has showed signiﬁcant improvement in the oral
bioavailability in rats (65% at 30 mg/kg) as against plain suspen-
sion (35%)31.
Emulsions/microemulsions based drug delivery systems have
been found useful in enhancing oral bioavailability of insoluble
molecules32. The microemulsions have also been used in
preclinical formulation development of insoluble NCEs33.
The torcetrapib which was considered to be blockbuster molecule
for treatment of elevated cholesterol inherently had poor absorp-
tion due to limited solubility in GI ﬂuids. The development of self
microemulsifying drug delivery system (SMEDDS) formulations
consisting of oils/surfactants/cosurfactants has led to increased
absorption of molecule in the dogs as compared to aqueous
suspension33. There was 30–40-fold increase in Cmax and AUC
when administered as SMEDDS under fasted conditions33. The
poor solubility was considered to be one of the problems in the
preclinical development and appropriate formulation development
ensured progress of molecule to clinical testing. However the
molecule was discontinued from late stage clinical testing due to
safety reasons34.
The cosolvent and surfactant based formulation approach has
been widely used to address the solubility issue in the preclinical
development35,36. The N-Epoxymethyl-1,8-naphthalimide (ENA) a
novel antiproliferative drug candidate with potent anticancer
activity was found to have poor solubility and stability in aqueous
systems; however, the use of ethanol and Cremophores EL has
resulted in a viable formulation necessary for further preclinical
development of the molecule. Similar solvent/surfactant based
system was used for formulation of taxols27. The general template
for screening of formulation for insoluble NCEs at discovery stage
has been described in the literature36. These examples have clearly
demonstrated that formulation/drug delivery technologies can
overcome issue of solubility in drug discovery/development.
However in our experience, given advent of these many technol-
ogies for solubilization, it is not always possible to formulate all
insoluble molecules. Certain rock solid molecules may still pose
problem and go undeveloped.2.2. Formulation approaches for improving permeability
Permeability of drugs across the GI membrane is one of rate
limiting step in the absorption of drugs. The solubility and
permeability of drugs together determine extent of oral absorption.
The physicochemical factors such as log P, molecular weight,
polar surface area, charge/ionization, number of hydrogen bond
donors and acceptors determine permeability of molecule37.
In general, hydrophobic small molecules with higher log P, lesserpolar surface area, will have greater permeability across biological
membrane. Unionized species are more favored for absorption
than ionized species. In addition, drug efﬂux mediated mainly by
transports such as P-glycoprotein (Pgp), a multidrug resistant
proteins (MRP) and organic cation transporters (OCT) lead to poor
absorption of drug molecules38. The low permeability of mole-
cules may hinder their development and several NCEs are
reportedly dropped during the discovery stage.
There are several methods reported in the literature for
enhancement of permeability and prevent the efﬂux of drug
molecules by transporters. The permeation of molecules occurs
by two pathways, transcellular uptake across epithelial cells and
paracellular passage through intercellular space. The improve-
ments in both paracellular and transcellular absorption has been
accomplished by the use of chemical enhancers. Diverse classes of
compounds including detergents, surfactants, bile salts, Ca2þ
chelating agents, fatty acids, medium chain glycerides, acyl
carnitine, alkanoyl cholines, N-acetylated a-amino acids, N-acety-
lated non-a-amino acids, chitosans, mucoadhesive polymers, and
phospholipids have been investigated for permeation enhance-
ment37,39. Many of these agents act as detergent disturb structure
of lipid bilayer leading to increased membrane ﬂuidity and
permeability. On other hand, certain agents act as calcium
chelators and disturb tight junction between epithelial cells. The
trimethyl chitosan reported to bind to components of tight junction
and widen the intercellular space39.
Various excipients which are commonly used in the pharma-
ceutical formulations are reported to be potent inhibitors of Pgp
mediated efﬂux of drugs. The cosolvents such as polyethylene
glycol, surfactants such as polysorbates, Vitamin E TPGS,
Cremophores, Poloxamers and dendrimers have been reported to
signiﬁcantly reduce Pgp efﬂux of drugs40. Coadministration of
cyclosporine, a Pgp substrate with paclitaxel has resulted in
enhanced absorption of paclitaxel in human41. Increased and
consistent absorption of cyclosporine from SMEDDS formulation,
Neorals could be partially due to bypassing of Pgp efﬂux during
the absorption42. The scientiﬁc efforts in enhancing permeability
of molecules have been successful to considerable extent. Several
techniques described in this section can be utilized in early stage of
drug discovery for salvaging of molecules with poor permeability.
However, these techniques have limitations and not all molecules
can be beneﬁted.2.3. Formulation/drug delivery approaches for addressing
metabolism and elimination
Fate of drug in the body depends on its susceptibility to
metabolizing enzymes. Most of drugs undergo metabolism before
excretion and very few drugs are excreted unchanged. Phase I
metabolism includes reactions such as hydroxylation and oxida-
tion. The phase II metabolism involves dervitization reactions such
as glucuronidation and sulfation43. The metabolism renders the
molecules more hydrophilic and amenable for excretion. Rate of
metabolism determines plasma half-life of molecule. Faster
metabolism leads to shorter half-life. Optimum plasma residence
of molecules is essential to elicit pharmacological action. Mole-
cules which show signiﬁcant activity in vitro often fail to produce
meaningful activity in in vivo conditions due to rapid metabolism
and resveratrol is one such molecule12. Molecule best in class, in
terms of activity may not progress to further development various
issues such as ADME, rather molecules with balanced properties
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address metabolism are discussed.
Many of the commonly used excipients have shown to reduce
metabolism of drugs in in vitro conditions. The surfactants such as
Tween 80, Cremophores EL and Solutols HS have reduced
metabolism of midazolam when coincubated with rat liver micro-
somes. The reduction of metabolism was up to 50% in case of
Solutols HS and Cremophores EL at 0.3% w/v surfactant
concentration45 and similar results were reported for colchicine
with these surfactants46. Intravenous pharmacokinetic studies
revealed that Solutols HS had signiﬁcant effect on clearance of
colchicine, clearance was signiﬁcantly reduced and Cmax was
increased, however effects were minimal on midazolam. The weak
cytochrome p450 (CYP) inhibitory effect of surfactant was
sufﬁcient to affect moderately metabolized colchicine47. In con-
trast, pharmacokinetic proﬁle of midazolam was unchanged
because of its rapid rate of clearance through metabolism48.
The amount of surfactant below the CMC after dilution with blood
was also attributed to lack of effects on metabolism as against
in vitro results. The surfactants have been reported to affect
pharmacokinetic proﬁle of anticancer drugs such as paclitaxel,
docetaxel, etoposide and doxorubicine45. The intravenous adminis-
tration of 2.5 mL/kg Cremophores EL, 10 min before dosing of
either doxorubicine or doxorubicinol has resulted in doubling of
AUC and Cmax and reduction of clearance to half for both the
drugs49. Hence coadministration of surfactants can be considered to
reduce metabolism of molecules during discovery stages, however
hypersensitivity reactions towards surfactants needs to be consid-
ered. Surfactants with better clinical tolerability must be used.
Another simple, safe and effective approach to stabilize the
molecule against metabolism is polymer conjugation. Reversible
or irreversible covalent attachment of polymer to small molecule
non-peptide drugs can result in reduced metabolism, increased
circulation time, improved activity and reduced toxicity13. The
shielding effects of polymer on drug molecules against enzymes/
chemicals result in reduced degradation. However, all molecules
may not be feasible for polymer conjugation. The molecules with
functional groups such as OH, COOH, NH2, SH can be explored
for polymer conjugation49. Various polymers, such as dextrans,
polyethylene glycol (PEGs), N-(2-hydroxypropyl)methacrylamide
(HPMA) and polyglutamic acid, have been explored for conjuga-
tion with drugs.
The polymer conjugation approach has been successfully
applied for improving safety, efﬁcacy, and the pharmacokinetic
proﬁle of small molecule drugs such as doxorubicin (DOX),
norﬂoxacine (NOR), campothecine (CAMP) and paclitaxol
(PTX)50–56. Numerous reports have been published on polymer
conjugation of doxorubicin. Doxorubicin-dextran polymer con-
jugates were extensively investigated. In mice, conjugate was
found to have a higher plasma level, which persisted for a long
time, and thus provided very effective passive targeting51. How-
ever, phase I clinical studies of the conjugate showed that the
conjugate was slightly more toxic than DOX itself. WHO grade IV
hepatotoxicity, grade III cardiotoxicity and grade III thrombocy-
topenia were some of the major clinical signs noticed. However,
polymer conjugate had a prolonged circulation time, with a dose
dependent elimination half-life of t1/2β of 2.69 to 11.58 h and t1/2γ
of 41.44 to 136.58 h (doses 12.5–40 mg/m2).
The campothecine–PEG conjugates were prepared using
glycine linker. The electronegativity of linker was found to
increase the stability of conjugates52. The alkylated glycine linker
further enhanced stability of conjugates. The activity of theseconjugates was similar to campothecine-20-PEG without glycine
linker which hydrolyzed rapidly in plasma. These results demon-
strate that despite being stable in plasma, campothecine–glycine–
PEG conjugates demonstrated good activity because of probable
hydrolysis of conjugates in cells to release parent molecule. This
way circulation half-life can be increased without affecting activity
and improving overall efﬁcacy.
Norﬂoxacin (NOR)–dextran conjugates were prepared and
evaluated for the targeted delivery to macrophages in liver to
maximize anti-tuberculosis treatment53. Norﬂoxacine was conju-
gated to dextran via tetrapeptide spacer, such as Gly–Phen–Gly–
Gly (GFGG), Gly–Phe–Gly–Gly (GFAL). The conjugates were
relatively stable in plasma and buffers, and slowly hydrolyzed in
the presence of cathepsin. The NOR–peptide–dextran–mannose
conjugates were also prepared to enhance targeting to macro-
phages. Although conjugates were less active against mycobacter-
ium than norﬂoxacin, it was envisaged that under in-vivo
conditions, conjugates would hydrolyze to native norﬂoxacin,
resulting in the desired therapeutic effect.
Paclitaxol has been conjugated to soluble polymers such as
polyethylene glycol54, micelle forming diblock polymer polyethy-
lene glycol–polylactide (PEG–PLA)55. The paclitaxol–PEG con-
jugated made via ester link, was found to undergo rapid hydrolysis
in plasma with t1/2 of 30 min. The PTX–PEG ester conjugates
were considered ideal for prodrugs and for parenteral formulation
to overcome solubility issues. However, PTX–PEG prodrugs were
found unsuitable for this use as long circulating drug delivery
systems. Paclitaxol was conjugated to PLA–PEG with an ester
bond, the conjugate was found to be active against H7402 liver
cancer cell line55. The authors concluded that paclitaxol was
released in the cells, and that polymer conjugation did not affect
the activity of paclitaxol. However, data on pharmacokinetic and
in vivo activity was not reported.
Recently, polymer conjugates of a metabolically very unstable
molecule resveratrol were prepared and evaluated56–58. It was
observed that RSV–PLA–PEG ester conjugates were found to be
relatively stable in plasma, displayed better pharmacokinetic
proﬁle with multifold higher Cmax and AUC than plain RSV.3. Proliposomal drug delivery: solution for drug delivery
needs in drug discovery and development
The lipid based drug delivery systems are suitable for both oral
and parenteral applications. Emulsions systems have been in use
for decades, the liposomal parenteral formulations were additions.
The lipid based drug delivery has been investigated extensively in
recent times. The proliposomal drug delivery is becoming increas-
ingly popular (Table 1). Proliposomes are basically powder
mixture of drug and lipid, intended to produce multilamellar
liposomes upon contact with aqueous media entrapping adequately
hydrophobic drugs59,60. The proliposomes have distinct advan-
tages over liposomes, as they are free ﬂowing powder can be
incorporated into solid dosage forms such as capsules or tablets.
In addition, simple process of preparation makes them more
suitable for industrial scale manufacturing59,60. The multilamellar
liposomes containing drug molecules formed from proliposomes
mixture are believed to be absorbed via lymphatic absorption.
Based on lipid composition and type of lipid, there can two
possible ways for absorption of entrapped drug. Firstly, certain
investigations suggest that intact liposomes may be absorbed via
endocytosis by enterocytes61. Due to considerable size, the
Table 1 Pharmaceutical applications of proliposomal formulations in drug discovery and development with examples.
Formulation Drug Developmental issues addressed Reference
Proliposomes beads with DSPC Glyburide Dissolution 63
Proliposomes beads with DSPC Halofrantine Bioavailability 64
Proliposomal beads with DSPC, cholesterol and Tween 80 Cromolyn sodium Permeability 65
HSPC/cholesterol/stearylamine Zaleplon Bioavailability and ﬁrst pass effect 66
Lipid formulation with phosphatidylcholine/cholesterol Vinpocetine Solubility limited bioavailability 67
Lipid formulation with phosphatidylcholine Silymarin Poor solubility in water/oils, poor bioavailability 68
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system circulation62. The formation of mixed micelles consisting
of lipids and bile salts would lead to passive diffusion of vesicles
across villi followed by chylomicron formation during the passage.
The chylomicrons are believed to be taken up by lymphatic
system62. It can be anticipated that sufﬁciently hydrophobic drug
molecules would remain in the hydrophobic core of micelles and
not exposed to external environments. Hence proliposomes can be
solution to issues related to solubility, permeability, Pgp efﬂux,
presystemic metabolism of drugs and can be considered as candidate
enabling technique during drug discovery. We brieﬂy summarize
some of proliposomal work carried out in our laboratory and other
research organizations.
The proliposomal formulations of glyburide were evaluated to
improve dissolution. The enteric coated proliposomal beads of
glyburide with distearoyl phosphatidylcholine (DSPC), showed
remarkable improvement in dissolution of glyburide, the dissolu-
tion in phosphate buffer pH 7.4 was more than 95% as against
37% from marketed formulation63.
Halofrantine, a highly lipophilic drug used to treat chloroquine
resistant plasmodium falciparum infection, has low and variable
bioavailability probably due to its lipophilicity. The enteric coated
proliposomal formulation of halofrantine with DSPC showed more
than 40% increase Cmax and 90%–100% increase in area under
curve (AUC) in rats compared to suspension of halofrantine64.
This increased and consistent absorption is believed to be because
of facilitated absorption and lymphatic uptake in the presence of
lipids bypassing solubility barrier.
Cromolyn sodium is an anti-inﬂammatory drug used in pro-
phylactic treatment of bronchial asthma and allergic rhinitis. It has
oral bioavailability of o1%. The proliposomal formulation with
lipid DSPC, cholesterol and Tween 80 showed nearly 7.5-fold
increase in Caco-2 permeability as against control cromolyn
sodium in phosphate buffered saline65. These investigations in
our laboratory clearly demonstrated applications of proliposomal
formulations in overcoming drug development barriers. These
observations have been clearly corroborated by results of inves-
tigation from other labs.
Zaleplon is a hypnotic drug indicated in insomnia and is a
potential anticonvulsant, reported to be poorly soluble in water and
has high ﬁrst pass effect. As a result, it has 30% oral bioavail-
ability after oral administration. However, there was 2–5-fold
increase in oral bioavailability was observed when administered as
proliposomal formulation66. Similarly, vinpocetine which is indi-
cated for cardiovascular disease was also found to be poorly
soluble and had suffered high ﬁrst pass effect. The oral bioavail-
ability was reported to be mere 7% in human. The proliposomal
formulation in rabbits showed remarked improvement in the
bioavailability with 3.5-fold increase compared to pure drug67.
Silymarin is poorly soluble both in water and oil, making it
difﬁcult to formulate as emulsion formulation, but it wassuccessfully formulated as proliposomes with an improved bioa-
vailability of 3.5-fold as against pure drug in beagle dogs68.
These examples have clearly demonstrated the potentials of
proliposomal formulation for ADME issues. It can be opined that
such formulation approaches can be very helpful in salvaging
molecules in the discovery stages. However, major limitations of
proliposomal drug delivery are, only hydrophobic molecules
which have greater afﬁnity towards lipids can be formulated as
proliposomes, mechanism of absorption is not clearly established,
and lack of in vivo-in vitro correlation. Effect of lipid digestion and
lipolysis on in vivo performance of delivery system needs greater
research attention. The hydrophilic drugs with intrinsic perme-
ability and metabolism issues may not be beneﬁted from this
technique. Nevertheless, proliposomes seems to be versatile
delivery system for BCS classes II and III drugs.4. Drug delivery strategies for improving drugability of
biologics
4.1. Protein formulation and stabilization
Formulation of biologics presents unique problems than non-
peptide small molecules. The inactivation of proteins, peptides and
DNAs happens not just by chemical degradation but also by slight
physical changes69,70. The physical changes that affect activity of
protein and peptide drugs include aggregation, precipitation,
adsorption onto surface and denaturation due to changes in
quaternary, tertiary and secondary structures. The chemical path-
ways involved in inactivation of biologics include deamidation,
oxidation, hydrolysis, racemization, beta elimination, and disulﬁde
exchange69,70.
The formulation efforts have been successful in addressing
various stability issues associated with proteins and peptides.
Several approaches have been reported to stabilize protein
formulations. Exclusion of water from the formulation can lead
to greater stability of products. The most common method to
remove water from product is freeze drying/lypholization. How-
ever, freeze drying not always leads to greater stability, phenom-
enon called “freeze concentration” would lead to drastic changes
in microenvironmental pH conditions during the freezing may lead
to cold denaturation of proteins70–72. However, inclusion of
stabilizer, such as mannitol, trehelose and sucrose, which acts as
cryoprotectant coupled with optimized freeze drying cycle, can
lead to greater stability of protein based products. Oily suspension
for injections was also reported for stabilization.
Additives: There are several excipients reported to affect
positively the stability of proteins. The inclusion of sugars in the
formulation increases the stability of proteins by minimizing
the thermodynamic activity of proteins which lead to aggregation.
List of sugars include mannitol, trehelose, maltose and fructose.
Table 2 List of PEGylated protein products.
Product Original biologic Therapeutic indication Purpose of PEGylation
Adagens (pegademase bovine) Bovine adenosine,
deamidase
Severe combined
immunodeﬁciency (SCID)
Increased serum half-life
Oncaspars (pegaspargase) Asparaginase Acute lymphoblastic leukemia Increased serum half-life,
less allergic reactions
PEG-Introns (PEGylated IFN-α2b) IFN-α2b Hepatitis C Increased serum half-life
Pegasyss (PEGylated IFN-α2a) IFN-α2a Hepatitis C Increased serum half-life
Neulastas (pegﬁlgrastim) G-CSF Neutropenia Increased serum half-life
Somaverts (pegvisomant) hGH mutein Acromegaly Increased serum half-life
MIRCERAs (PEGylated epoetin-β) Epoetin-β Anemia associated with chronic
renal failure
Increased serum half-life
Cimzias (certolizumab pegol) Anti TNF Fab Rheumatoid arthritis and Crohn0s disease Increased serum half-life
Macugens or Macuverses (pegaptanib) Anti-VEGF aptamer
(an RNA oligo-nucleotide)
Treatment of ocular vascular
disease
Longer residence at site of
action, improved efﬁcacy
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and reported to prevent aggregation73. Cyclodextrins are reported
to encapsulate proteins and stabilize74. Surfactants such as
poloxamers, polysorbate 80 and polysorbate 20 have been reported
to prevent aggregation of proteins. The surfactants have been also
found to prevent aggregation during the freeze drying process and
adsorption onto surfaces75–78. The amino acids such as glycine,
lysine and arginine have prevented the aggregation, adsorption of
proteins and improved thermal stability of proteins79–82. Inclusion
of salts/buffering agents has resulted in increased solubility and
thermal stability, and minimized aggregation of proteins83,84. The
use of chelating agents such as edetic acid (EDTA), Tris
(tromethamine) has shown to stabilize proteins against chemical
degradation69. Similarly, the fatty acids and lipids such as
phosphatides are reported to stabilize the nucleic acids against
chemical degradation85,86. These studies have clearly demon-
strated role of formulation in retaining activity of biologics.4.2. Drug delivery systems to improve efﬁcacy of biologics
Although the stability of proteins has been improved by conven-
tional formulations, the fate of biologics in the body remained
challenge. There have been several innovations to improve
tolerability and enhance therapeutic effects of proteins in the
body. The injection of protein products in the body may precipitate
unwanted biological responses leading to early clearance of the
products. The immunological and antigenic response may lead to
early clearance of proteins from the circulation. The proteins are
also prone to degradation by proteolytic enzymes13. The small
molecular weight proteins are eliminated by kidney ultraﬁltra-
tion13. The issue of rapid clearance of proteins from body has been
addressed successfully by conjugating with polymers. The protein-
polymer conjugation has reported to prevent immunological and
antigenic responses, stabilize against proteolytic enzymes, improve
solubility and decrease elimination by kidney ultraﬁltration13,50.
The conjugation of polymer to drug/protein reported to shield the
molecule against chemical/enzymatic degradation and larger
molecular weight of polymer reduces kidney ultraﬁltration50. In
addition, the polymer conjugates improve cellular uptake of
conjugated via adsorption-endocytosis mechanism50. Although
there have been observations where the activity of protein reduced
after polymer conjugation, however the increased plasma concen-
tration and prolonged circulation time would counter the reduced
activity and result in overall improved efﬁcacy87. The polymerconjugation was also successful in passive and active targeting,
which will be discussed in subsequent sections. The covalent
linkage of polyethylene glycols to proteins is commonly known as
PEGylation of proteins. The PEGs are considered to be safe and
PEGylation is the most common technique used to improve
therapeutic beneﬁts of protein drugs. The list of PEGylated
proteins approved in the United States is given in Table 2. The
various multiparticulate drug delivery systems, such as liposomes,
microparticles and nanoparticles, have been developed to release
proteins and peptides slowly for longer time but there is no
commercial success yet88. However, given the amount of research
work being undertaken, there would no surprise if the particulate
delivery system with protein hits market in coming years. There
are several reports on vaccines loaded nanoparticle formulations.
The formulation of new castle disease virus (NDV) vaccine in the
form of nanoparticles with mucoadhesive polymer chitosan
showed 100% protection of chickens against NDV infection after
oral and nasal administration89. The plain NDV vaccines showed
40–80% protection. Similarly, IgA loaded chitosan nanoparticles
containing pertussis toxin improved nasal absorption and increased
immune response90. The same nanoparticles showed multi-fold
increase in the immune response after subcutaneous injection as
against pure pertussis toxin91. These preliminary studies showed
promise of nanoparticles in improving efﬁcacy of vaccines.
Further, exploration is necessary to achieve signiﬁcant success
and to demonstrate proof of concept. Most widely used protein
drug is insulin and it has attracted lot of researches in last couple
decades, mainly on noninvasive delivery. The inhalation product,
Exubera was approved by FDA and was later withdrawn from the
market. The oral liposomal formulation of insulin, PEGylated
insulin (IN-105, Oral), Oral-Lyn (buccal) are being tested in
clinics. The IN-105 for oral delivery and Oral-Lyn for buccal
delivery seems to promising in small clinical trials92. However,
larger clinical trials are necessary to prove their effectiveness.
Their successful completion of clinical trials would lead to
dramatic change in research and development of protein based
drugs. This would revolutionize drug development program and
shift paradigm of drug discovery towards therapeutic proteins.5. Drug delivery strategies for improving efﬁcacy of CNS
drugs
The number of people suffering from CNS disorders is on
increasing trend, yet very few drugs getting approved for the
Figure 3 Representative diagram of blood brain barrier and major pathways of drug transport across the BBB. Modiﬁed from Ref. 100.
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from CNS disorders93. The global burden from CNS diseases is
expected to rise to 14% in 202094. It has been reported that most of
the CNS drug development efforts (99%) are directed towards
ﬁnding new molecule, only meager 1% of efforts are on delivery
of molecules to brain95. The main problem encountered in the
delivery of drugs to brain is the presence of various barriers in the
brain which prevent entry of drugs, other chemicals and toxins.
The main barrier is BBB. The BBB is situated at brain and blood
interface, is mainly composed of brain vascular endothelial cells
and is barely penetrated (Fig. 3). Other cells, such as pericytes,
astrocytes and neuronal cells, also play an important role in the
functioning of BBB. Main function of BBB is to maintain home-
ostasis of the brain. The other barriers, blood-cerebrospinal ﬂuid
(CSF) barrier, blood-spinal barrier, choroid plexus and brain-CSF
barrier also restrict movement of drug molecule into brain96–98. The
molecules with favorable physicochemical properties will reach the
brain. The molecular weight, log P, polar surface area and charge
play the important role in brain permeation of drugs99. The ideal
drug candidate should have MWo450 Da, log P 1.5–2.5, polar
surface are of 65–70 Å2. The molecules bearing positive charge at
pH 7–8 and those with tertiary nitrogen in the structure will have
greater BBB permeability99.
Based on physicochemical properties there are several absorp-
tive pathways available for drug transport across the BBB. The
hydrophobic small molecules with log P with MWo450 are
absorbed by passive transcellular diffusion, some of water soluble
small molecules reported to be transported via paracellular route
across intercellular spaces. The essential nutrients, such as glucose,
amino acids and nucleosides, are taken up by facilitated/carrier
mediated transport. Lipid soluble amphiphilic molecules, such as
cyclosporine and azidothymidine, are reported to be substrate of
Pgp and undergo efﬂux process after passive diffusion to be back
into system circulation. Other pathway for transport of essentialproteins and peptides is endocytosis, the molecules, such as
insulin, transferrin and leptin, are internalized by receptor
mediated endocytosis, whereas histone and cationic albumin
undergo adsorption mediated endocytosis (Fig. 3). Despite these
many pathways for absorption, the delivery of drugs to brain is
limited because of selective nature of BBB for passive and
facilitated diffusion, rigid tight junction, active transport proteins
for efﬂux of amphiphilic molecules100.
Apart from the drug design tool to increase the CNS delivery of
drugs by increasing lipophilicity, there are several drug delivery
techniques described in the literature for the CNS delivery of drugs
and are described in following sections.
5.1. Chemical delivery systems: prodrugs/lipid conjugates
This mode of drug delivery system involves modiﬁcation of drug
physicochemical properties, especially the lipophilicity of mole-
cule by prodrug formation or conjugation with lipidic material.
This technique is based on fact that codeine and heroine acetylated
prodrugs of morphine show greater activity than the morphine
because of increased lipophilicity and brain penetration. In the
brain, these prodrugs are hydrolyzed back to morphine, a more
polar molecule, which gets locked in the brain100. The delivery of
horseradish peroxide to brain was enhanced 2–3-fold after con-
jugation with stearic acid101. However, increased lipophilicity may
also increase the distribution of drugs to other body tissues leading
to faster elimination of drugs from systemic circulation102.
5.2. Nasal delivery
The olfactory organs, such as nasal cavity, have reasonably good
penetration of olfactory neurons surrounded by a sleeve of
arachnoid membrane containing CSF. This connection enable
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involving the nasal perfusion of hydrophilic sulfonamides in the
rats revealed that there was signiﬁcant amount of sulfonamides in
CSF compared to IV administration. The plasma levels of
sulfonamides after IV and nasal administrations were not sig-
niﬁcantly different, indicating direct transfer of nasally adminis-
tered drugs into brain via olfactory neuronal connection103. Similar
ﬁndings were reported for cephalexin, where the CSF concentra-
tion of cephalexin was signiﬁcantly higher when administered
intranasally compared to IV and intradueodanal dosing despite
similar plasma concentration104. This study once again revealed
nose–brain direct delivery. In addition to simple nasal formula-
tions, the formulations with mucoadhesive polymers, nanoparticles
can be considered to increase residence time of formulation in the
nasal cavity in order to increase brain uptake of drugs.
5.3. Modulation of BBB
Another approach for enhancing the brain permeation is to
modulate BBB. There have been reports suggesting use of
hypertonic mannitol solution to open up the BBB. The injection
of 25% mannitol solution via carotid artery has resulted in opening
of BBR and subsequent administration of drugs via same artery
resulted in the enhanced penetration into brain. The enhanced
permeation could be due to shrinkage of cells leading to opening
of paracellular route. This osmotic opening has resulted in 10–100-
fold increase in methotrexate delivery to brain. The 1-O-heptyl-
triglycerol and bradykinin were also found to open up BBB. The
modulation of BBB may come with risk, potential toxins and
viruses may get entry into brain100.
5.4. Carrier mediated transport
There are several transporters identiﬁed in the BBB which
facilitate solute transport across the BBB. Medium chain fatty
acid transporters, large neutral amino acid carrier, monocarboxylic
acid carrier, organic cation transporter, purine carrier, nucleoside
carrier, hexose/glucose transporter are identiﬁed in the brain.
Based on understanding of stereochemical requirements for
transporters, the drugs/drug delivery systems can be constructed
to target these transporter proteins for uptake into brain100.
However, glucose transporter such as GULT1 is believed to be
very stereoselective in picking up molecules, in such case
designing of false/pseudosubstrate for brain transport is compli-
cated. The antiepileptic drug valproic acid is reported to be
transported across via medium chain fatty acid transporter. The
in situ brain perfusion study in rats demonstrated that valproic acid
is transported through medium chain fatty acid transporter,
presence of short chain fatty acids and ketoacids did not inhibit
brain uptake of valproic acid105. However, the medium chain fatty
acids (C6–C12) inhibited the brain uptake of valproic acid
suggesting medium chain fatty acid transporter involvement in
the uptake of valproic acid.
Large neutral amino acid transporter (L system, LAT1) is
reported to have wide selectivity in transporting molecules100. The
in situ rat brain perfusion studies carried out for tyrosine
conjugated ketoprofen, showed concentration dependent uptake
of conjugate. The ketoprofen itself is not substrate for LAT1;
however, conjugation of tyrosine enhanced the brain uptake of
drug. The coperfusion of LAT1 inhibitor reduced the brain uptake
of conjugated ketoprofen suggesting LAT1 mediated mechanismof uptake106. In another study, the phenylalanine prodrugs of
valproic acid have shown greater afﬁnity for LAT1. Meta-
substituted phenylalanine prodrugs displayed 10-fold higher afﬁ-
nity for LAT1 and 2-fold higher brain uptake than parasubstituted
analogues107. Interestingly, the valproic acid has been reported to
be substrate for medium chain fatty acid transporter.
Despite stringent selectivity of GULT1 transporters, there are
studies suggesting possible GULT1 mediated uptake of glucose
prodrugs. The glucose prodrugs of ketoprofen and indomethacin in
the brain perfusion studies displayed inhibitory effect on glucose
uptake by brain and prodrugs were able to cross BBB in temperature
dependent manner107.
Endocytosis mechanism has been explored for brain delivery of
drugs. The receptor mediated and adsorption mediated endocytosis
are reported for brain delivery. The abundance of transferrin
receptors on brain vascular endothelial cells provides opportunity
for delivery of drugs to brain. Role of transferrin in brain delivery
has been elegantly summarized in the literature108. The transferrin
itself has limited application for brain targeting due to saturation of
receptors due to endogenous transferrin. The Antitransferrin
receptor (OX26) monoclonal antibodies against the rat transferrin
receptor have displayed greater afﬁnity for protein and larger
application in the drug delivery. OX26-drug conjugates can be
prepared using linker based direct conjugation of suitable drug to
OX26, The drug can also be conjugated to OX26 via PEG spacer
or biotin/avidin spacer108,109. Perfusion of OX26 conjugated gold
nanoparticles through carotid artery revealed endocytosis of
nanoparticles in brain capillary endothelium109. In another study,
pharmacokinetic and brain distribution studies of 3H-daunomycin
in liposomes, PEG–liposomes and OX26-PEG–liposomes was
evaluated in rats110. The delivery of daunomycin to brain has
increased 3-fold in case of OX26 coupled liposomes compared to
free daunomycin and daunomycin in plain liposomes. The PEG
conjugated liposomes did not deliver the drug to brain. The
proteins drugs were also targeted to brain via receptor mediated
endocytosis. ApoB conjugated proteins were successfully taken
into brain via low density lipoprotein receptor mediated endocy-
tosis110. The cationized albumin was found to undergo adsorption
mediated endocytosis into brain. After intravenous injection of
cationized and plain rat serum albumin to rats, the mean brain
volume of distribution of cationized albumin was found to be
46 mL/g for cationized albumin compared to 9.3 mL/g for plain
serum albumin111. These results indicate adsorption of cationized
albumin to endothelial cells followed by endocytosis. The catio-
nized albumin can be considered as vehicle for brain delivery
of drugs.
Coadministration of drugs inhibiting efﬂux proteins has been
found to increase the brain delivery of substrate drugs. The clinical
study was conducted to determine effect Pgp inhibitor drug
on distribution of substrate drug to brain. This study revealed
that there was enhanced supply of drug to brain when dosed with
Pgp inhibitor. The antidiarrheal drug loperamide is potent
opiate. However, its inability to cross BBB makes the drug safe
without any CNS side effects and abuse potential. However, when
16 mg of loperamide was administered with 600 mg of quinidine,
a Pgp inhibitor, there were signiﬁcant opiate like effects
observed112. The respiratory response to carbon dioxide rebreath-
ing indicated that there was indeed respiratory depression. In
contrast, there was no respiratory depression observed when the
same dose of loperamide was given with placebo112. These
investigations revealed that it possible to enhance BBB penetration
of drugs if the Pgp efﬂux is the barrier for BBB penetration.
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taken into account and intravenous administration of safe exci-
pients such as poloxamers can be considered for inhibiting efﬂux.
Direct injection of drugs into brain parenchyma, inraventricu-
larly or intrathecally, has been reported; however, risk of dama-
ging brain tissues is high100. In conclusion, there are several drug
delivery systems available for improving the delivery to brain. The
LAT1 targeting, OX26 targeting and inhibition of efﬂux are
promising. However, further exploration and clinical investiga-
tions are essential for their application in improving efﬁcacy of
drugs. Nevertheless, it is good to divert more attention to brain
drug delivery to salvage many clinical candidates with promising
therapeutic potential.6. Drug delivery strategies for addressing efﬁcacy/safety via
targeting
The ability of drug to exert pharmacological actions depends on
rate and extent at which the drug reaches site of action113. The
desired biological action can be achieved if adequate amount of
drug is available in the affected tissues. Presence of drug molecule
beyond tolerable level in the body tissues other than site of action
would precipitate unwanted biological responses leading to
toxicity. Discontinuance of many molecules in the discovery and
development program could be attributed to poor accumulation of
molecules in the site of action and rather wide distribution to other
parts of the body leading to lack of efﬁcacy and increased toxicity.
In this section, we discuss brieﬂy the examples of successful drug
targeting and their possible application during discovery/develop-
mental stages. The drug targeting is usually achieved by either
passive targeting or active targeting. The passive targeting
involves spontaneous accumulation drug delivery systems in the
diseased parts of the body. On other hand, active targeting
involves targeting moiety to drug or drug carrier to enhance pick
up by target cells. The tumor is highly vascularized in response to
increased demand for nutrition supply from rapidly growing tumor
cells. The tumor vascular endothelium is more porous, this allows
leakage of nano-drug carriers into tumor through pores. The
inefﬁcient lymphatic drainage and slow venous blood return will
allow drug carriers to stay longer time in the tumor114. This
process is regarded as enhanced permeation and retention (EPR).
The cancer drug candidates are usually more toxic than other
therapeutic molecules and hence drug targeting has been exten-
sively applied to cancer treatment114.
The Doxils was ﬁrst liposomal formulation approved by
United States Food and Drug Administration (FDA), the formula-
tion is PEGylated liposome encapsulating doxorubicin. The
free doxorubicin has circulating half-life of 0.2 h and AUC of
4 mg  h/mL; in contrast, Doxils has half-life of 55 h and AUC of
900 mg  h/mL115. More than 90% of doxorubicin remained in
liposomes during the circulation116. The liposomal formulation
avoided repeated administration of drug and showed reduced
clinical cardiotoxicity116,117. Myocets is another doxorubicin
liposomal formulation with circulating half-life of 2.5 h. It is
reported to be safer than doxorubicin118. DaunoXomes and Onco-
TCSs are approved non-PEGylated liposomal formulations of
daunorubicin and vincristine. The Genexol-PM, a novel polymeric
micelles encapsulating Paclitaxel, exhibited signiﬁcant efﬁcacy
and better safety proﬁle than Cremophores EL contained for-
mulations119. The Preclinical studies in mice revealed that theconcentration of paclitaxel in tumor for micelle formulation were
higher than plain paclitaxel120.
Active targeting to tumor has also been investigated. Abrax-
anes, albumin bound nanoparticles containing the paclitaxel,
demonstrated higher response rates, a better safety proﬁle com-
pared with conventional paclitaxel, and improved survival in
patients receiving it as second-line therapy121. The albumin
nanoparticles were reported to be actively transported into cancer
cells via secreted protein acidic rich in cysteine (SPARC) mediated
transport122. The oxaliplatin is novel cisplatin derivative with
reduced kidney toxicity; however, this drug is only effective when
given with 5-ﬂurouracil. The oxaliplatin is reported to partition
rapidly into erythrocytes and this was attributed to lack of
anticancer activity when given alone. The transferrin–PEG–lipo-
somes containing oxaliplatin showed improved circulation time,
reduced partitioning, and increased localization of oxaliplatin in
tumor123. Intravenously administered transferrin–PEG–liposomes
containing oxaliplatin suppressed the tumor growth more effec-
tively than PEG–liposomes, bare liposomes and free drug123. The
increased efﬁcacy with transferrin liposomes could be due to
increased circulation time and transferrin mediated endocytosis of
liposomes into cancer cells.
Drug-polymer conjugation was also explored for tumor target-
ing. The doxorubicin conjugated to HPMA polymer lysosomally
cleavable tetrapeptide linker. The polymer conjugate was labeled
with galactosamine. After intravenous administration to 32
patients, 16.9% of dose was accumulated in liver and 3.3% of
dose was seen tumor after 24 h post dosing124. However, there was
no targeting seen with conjugates without galactosamine. The
amphotericin B is potent antifungal drug but has narrow ther-
apeutic index due to its toxicity. The liposomal formulation
(AmBisome) was successfully delivered drug to fungi cells with-
out causing systemic toxicity125. Various other targeting systems
and delivery to other organs such as heart, lungs and athero-
sclerotic lesions are described in the literature113. These studies
suggest that novel targetable drug delivery systems can be
designed to enhance the developability of molecules in the
discovery and development stage.7. Timed release drug delivery and applicability in drug
discovery and development
The efﬁcacy and safety of drugs is again dependent on the
concentration of drug in the systemic circulation. The level above
maximum safety concentration would lead to toxicity and level
below the minimum effective concentration results in lack of
efﬁcacy. In order to deliver the drug at desired level, timed release/
modiﬁed release formulations proven effective. Usually the
modiﬁed release formulations are designed for existing drugs for
better efﬁcacy and safety proﬁle; however, proper application
timed release formulations will certainly help the clinical candi-
dates in reaching desired clinical endpoints. Some examples of
timed release formulations are discussed here.
The metformin, an anti-diabetic drug, is suggested be taken
orally twice a day up to 1500 mg for maintaining blood glucose
levels within acceptable limits. The common side effects of
metformin are stomach upset and nausea. The extended release
oral formulations have been tested clinically to improve efﬁcacy
and safety126. The extended formulations containing the 2000 mg
of metformin showed signiﬁcant decrease in glycated hemoglobin
(A1C) levels compared to immediate release formulation (1500 mg
Figure 4 Flow chart for showing various formulation/drug delivery solutions for drug attrition during discovery and development.
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naive patients and 465 years old patients (7.33% and 7.23% for
immediate release formulation). The GI side effects were either
reduced or not observed in case of extended release formulations.
This could be due to slow and steady release of drug without overshooting plasma level while maintaining the desired therapeutic
concentration over the time.
Minocycline is oral antibacterial drug used to treat variety of
infection and commonly prescribed for treatment of acne. The
immediate release formulations reported to produce vestibular
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was tested clinically for treatment of acne and incidence of
vestibular side effects. The extended release formulation at
1 mg/kg body weight signiﬁcantly reduced the number of inﬂam-
matory lesions. The reports of vestibular adverse events were
comparable to placebo group127. The formulation was found
effective in treating acne without signiﬁcant adverse effects.
Similarly, extended release formulation of niacin (NIASPANs)
was reported to provide consistent and desired plasma level
required for pharmacological activity and incidence of liver
toxicity were reported to be signiﬁcantly less than sustained
release formulations128. The extended release formulation was
found efﬁcacious in treating hyperlipidemia and liver related
adverse effects were comparable to placebo group128. The delayed
release formulations of fenoﬁbric acid was found effective in
treating hyperlipidemia alone or in combination with statins129.
Another nice example of formulation playing important role in
developability of molecule is didanosine formulation. Initially,
didanosine was administered as solution/suspension with antacids/
buffered tablet. The didanosine was believed to degrade in acidic
pH conditions of gastric ﬂuid and cause side effects. Buffered
formulations were reported to reduce the toxicity of molecule.
Recently, enteric coated formulation has been approved and has
displayed comparable pharmacokinetic proﬁle with improved
tolerability130. Brieﬂy, these examples clearly demonstrate that
timed release formulations have greater potential in salvaging
molecules with toxicity/safety concerns. Overall, summary of
formulations/drug delivery systems contributing to improved
clinical applications or overcoming developmental barriers of drug
molecules is shown in Fig. 4.8. Exploring non-oral and non-parenteral formulations/drug
delivery to improve drugability of molecules during discovery
and development stages
The various issues hindering development of molecules into drug
candidate can be overcome by using drug delivery rout alternative
to oral and parenteral applications. Nasal delivery route for
vaccination and enhancement of brain delivery has been discussed
in previous sections. Routes such as buccal and transdermal can be
explored during discovery and development. Routs such as
sublingual, buccal, rectal and nasal can be difﬁcult to establish
in preclinical animal models, such as rat and mice. In addition,
establishing pharmacokinetic and pharmacodynamic correlation in
animal model will be little difﬁcult. Alternative routes can
minimize ADME related issues; however, delivery of drugs to
speciﬁc organ and stabilizing the drug in circulation cannot be
achieved. Moreover, protein/peptide drugs would not be beneﬁted
from alternative routes of delivery because of permeability issues.
Transdermal drug delivery has been explored to improve efﬁcacy,
tolerability and compliance of several drugs belonging to various
classes131. Some of the drugs were available as oral formulations.
Interesting example is development of transdermal and buccal
formulations of testosterone132,133. The testosterone, which under-
goes complete metabolism when given orally, needs injection.
Development of transdermal patch overcome need of repeated
injection and provided needed drug levels for almost 24 h132.
Similarly, sustained release buccal tablets were found useful with
just twice a day dosing but economical than transdermal patch133.
When new molecules suffer from drawbacks of ﬁrst passmetabolism or have shorter plasma half-life than alternative
delivery, routes such as transdermal can be considered.9. Conclusions
It is evident from the review of literature and clinical reports that
formulation and drug delivery systems offered viable solution to
drug molecules with inherent ADME barriers, safety and efﬁcacy
issues. Protein based drugs have greatly beneﬁted drug delivery
systems such as polymer conjugation. The physical and chemical
stability of protein drugs in conventional injectable formulations
has been addressed successfully with inclusion of stabilizing
excipients, change of process or pH of formulation. The targeting
of drugs to different organs and tumors has been proved clinically.
The literature data suggest limited but reasonable success of drug
delivery systems in enhancing the drug supply to brain. Timed
release formulations have demonstrated favorable effects on safety
and efﬁcacy of drugs. These observations suggest that formulation/
drug delivery approaches can be very useful tool in reducing
attrition of molecules during the drug discovery and development.
There needs increased emphasis on the application of formulation/
drug delivery at early stages of drug development path. The
research in drug delivery should be directed more towards
improving developability of clinical candidates rather already
approved drugs. There are many challenges that formulation
science has not dealt with and hence leave a lot of scopes for
further investigations. Oral delivery of proteins and peptides has
not proven successful in clinics. Despite signiﬁcant progress in
drug targeting, clinical success of targeted delivery is limited
expect to those system with passive targeting to tumor such has
liposomes. There needs concerted efforts from formulation and
molecular biology scientists to identify targetable cellular compo-
nents and respective targeting markers for delivery devices.
Research on particulate oral drug delivery has not yet successful
completely. The oral delivery of drugs via nanoparticles and
liposomes needs greater research attention. Identifying targeting
ligands to improve uptake of nanoparticles/liposomes via lympha-
tic and endocytosis/carrier mediated transport across GIT is
necessary. Even prodrug design did not completely explore the
possibility of active transport across GIT. Success in these areas
would almost solve problems with oral delivery.References
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